ORPHA:424046
Acinar cell carcinoma of pancreas
Also known as: Pancreatic acinar cell carcinoma
Publications
1,170
Trials
28
Interventional, condition-specific
Researchers
1,541
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A very rare, malignant, epithelial tumor of the pancreas characterized, macroscopically, by a usually large, well-circumscribed, fully or partially encapsulated, solid mass, often with hemorrhage, necrosis and cystic changes, in any portion of the pancreas and, histologically, by neoplastic cells with variable degrees of differentiation and morphology, ranging from acinar structures similar to normal pancreatic acini to large sheets of poorly differentiated neoplastic cells. Presenting symptoms are typically non-specific and include abdominal pain, weight loss, vomiting, nausea, and/or, less commonly, jaundice. Immunohistochemical evidence of acinar-specific products is observed. Association with Lynch syndrome, familial adenomatous polyposis, and pancreatic panniculitis has been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006346
- UMLS:C0279661
- NCIT:C7977
Additional Mondo synonyms (9)
Pancreatic acinar cell cancer · acinar cell adenocarcinoma of pancreas · acinar cell adenocarcinoma of the pancreas · acinar cell carcinoma of pancreas · acinar cell carcinoma of the pancreas · carcinoma of pancreatic acinar cell · pancreas acinar cell adenocarcinoma · pancreatic acinar cell adenocarcinoma · pancreatic acinar cell carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,170 matched papers (678 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
28 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,170
1,170 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,170 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
678 in the last 10 years · low confidence
Phrase hits: 1,170 · MeSH hits: 0
Who's working on it?
1,541
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li C5 papers · 2025
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Papers in Europe PMC - 02Liu Y5 papers · 2026
Department of Satistics, Hebei University, Baoding, 071000, China.
Papers in Europe PMC - 03Simon R5 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 04Bernreuther C4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 05Burandt E4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 06Büscheck F4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 07Dum D4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 08Fraune C4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 09Gorbokon N4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC - 10Hinsch A4 papers · 2025
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
28
interventional trials for this specific condition
28 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 2 trials are registered for acinar cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
28 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.8th percentile).
low confidence · 95.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
28 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04150042·RECRUITING·SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Not reviewed·Conditions: Pancreatic Adenocarcinoma Metastatic · BRCA1 Mutation · BRCA2 Mutation · Pancreatic Acinar Cell Carcinoma·Matched via name phrase
- NCT04858334·RECRUITING·APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Not reviewed·Conditions: Pancreatic Acinar Cell Carcinoma · Pancreatic Adenosquamous Carcinoma · Pancreatic Squamous Cell Carcinoma · Resectable Pancreatic Acinar Cell Carcinoma·Matched via name phrase
Broader category: acinar cell carcinoma
2
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04657068·RECRUITING·A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Not reviewed·Conditions: Advanced Cancer · Metastatic Cancer · Ovarian Cancer · Primary Peritoneal Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- isrctn·ISRCTN63154609·Recruiting·A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acinar cell carcinoma of pancreas — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acinar cell carcinoma of pancreas" OR "Acinar cell carcinoma of the pancreas" OR "Pancreatic acinar cell carcinoma" OR "Pancreatic acinar cell cancer" OR "acinar cell adenocarcinoma of pancreas" OR "acinar cell adenocarcinoma of the pancreas" OR "carcinoma of pancreatic acinar cell" OR "carcinoma of the pancreatic acinar cell" OR "pancreas acinar cell adenocarcinoma" OR "pancreatic acinar cell adenocarcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acinar cell carcinoma of pancreas" OR "Acinar cell carcinoma of the pancreas" OR "Pancreatic acinar cell carcinoma" OR "Pancreatic acinar cell cancer" OR "acinar cell adenocarcinoma of pancreas" OR "acinar cell adenocarcinoma of the pancreas" OR "carcinoma of pancreatic acinar cell" OR "carcinoma of the pancreatic acinar cell" OR "pancreas acinar cell adenocarcinoma" OR "pancreatic acinar cell adenocarcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 28 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acinar cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1170) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T15:55:47.942Z
